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Abstract 
PET and PET/CT using [
11C]- and [
18F]-labelled choline derivates is increasingly being used for 
imaging of primary and recurrent prostate cancer. While PET and PET/CT with [
11C]- and 
[
18F]-labelled choline derivates in patients suffering from biochemical recurrence of prostate 
cancer has been examined in many studies that demonstrate an increasing importance, its role 
in the primary staging of prostate cancer is still a matter of debate. 
Morphological and functional imaging techniques such as CT, MRI and TRUS have demon-
strated only limited accuracy for the diagnosis of primary prostate cancer. Molecular imaging 
with PET and PET/CT could potentially increase accuracy to localize primary prostate cancer. 
A considerable number of studies have examined the value of PET/CT with [
11C]- and [
18F]- 
labelled choline derivates for the diagnosis of primary prostate cancer with mixed results. 
Primary prostate cancer can only be detected with moderate sensitivity using [
11C]- and 
[
18F]choline PET and PET/CT. The detection rate depends on the tumour configuration. 
Detection is also limited by a considerable number of microcarcinomas that cannot be de-
tected due to partial volume effects. Therefore small and in part rind-like tumours can often 
not be visualized. Furthermore, the differentiation between benign changes like prostatitis, 
high-grade intraepithelial neoplasia (HGPIN) or prostatic hyperplasia is not always possible. 
Therefore, at the present time, the routine use of PET/CT with [
11C]- and [
18F]-labelled 
choline derivates cannot be recommended as a first-line screening procedure for primary 
prostate cancer in men at risk. A potential application of choline PET and PET/CT may be to 
increase the detection rate of clinically suspected prostate cancer with multiple negative 
prostate biopsies, for example in preparation of a focused re-biopsy and may play a role in 
patient stratification with respect to primary surgery and radiation therapy in the future. 
Key words: choline PET, PET/CT, Prostate Cancer 
Introduction 
Prostate cancer is currently the highest prevalent 
form of cancer in men (192,280 cases, 25% of all inci-
dent  cases)  and  the  second  most  common  cause  of 
cancer associated deaths (9%) in the USA [1-2]. The 
gold standard for diagnosing prostate cancer is his-
topathological examination of prostate tissue obtained 
by prostate needle biopsy. Commonly used diagnostic 
tools in the evaluation of prostate cancer are digital 
Ivyspring  
International Publisher   Theranostics 2012, 2(3) 
 
http://www.thno.org 
319 
rectal examination, measurement of serum levels of 
prostate specific antigen (PSA), transrectal ultrasound 
(TRUS) as well as TRUS-guided biopsies [2]. Beside 
these diagnostic modalities, morphological and func-
tional imaging methods such as computed tomogra-
phy  (CT),  magnetic  resonance  imaging  (MRI),  bone 
scintigraphy  and  positron  emission  tomography 
(PET, PET/CT) are also used. 
Morphological  imaging  techniques  such  as 
TRUS, CT and MRI have demonstrated only limited 
accuracy  for  primary  diagnosis  of  prostate  cancer, 
recurrent disease as well as advanced disease. Con-
cerning diagnosis of primary prostate cancer, CT has 
shown limited specificity. Furthermore the detection 
of lymph node metastases is limited by morphological 
imaging such as CT and MRI; first, small lymph node 
metastases cannot be visualized; second, size as only 
criterion might not be sufficient to detect metastatic 
involvement  in  lymph  nodes.  For  the  detection  of 
bone metastases, CT may be of use in imaging tra-
becular changes caused by metastasis which appear 
relatively  late  in  the  course  of  bone  metastases. 
Therefore  increasing  the  diagnostic  performance  in 
prostate  cancer  imaging  remains  a  major  challenge. 
Combined  molecular  and  morphological  imaging 
techniques such as PET/CT may improve the diag-
nostic accuracy in imaging prostate cancer. 
PET/CT  based  on  increased  glycolysis  using 
[18F]fluorodeoxyglucose  (FDG)  has  shown  only  lim-
ited  sensitivity  for  the  detection  of  differentiated 
prostate carcinomas and imaging of recurrent prostate 
cancer in various studies [3-5]. Increased FDG uptake 
and  accumulation  is  regularly  only  found  in  dedif-
ferentiated,  aggressive  and  metastasized  prostate 
cancer.  Other  PET-  and  PET/CT  tracers  have  been 
introduced for diagnosing prostate carcinoma based 
on  an  increased  androgen  receptor  expression 
([18F]fluorodihydrotestosterone  (FDHT)),  fatty  acid 
synthesis  ([11C]acetate),  amino  acid  transport  and 
protein synthesis ([11C]methionine) as well as choline 
turnover  by  [11C]-/[18F]labelled  choline  derivates 
[5-11]. Promising results have been obtained for the 
use of PET- and PET/CT with [11C]- and [18F]-labelled 
choline derivates, for an overview see Krause et al. 
[12]. The use of choline for imaging prostate cancer is 
based on increased phosphorylcholine levels and an 
elevated  phosphatidylcholine  turnover  in  prostate 
cancer cells [13-14]. After uptake into the tumor cell 
through a high affinity transporter system, choline is 
metabolized by choline kinase - which is the first step 
of the Kennedy pathway - and is incorporated into the 
phosphatidyl membrane. Key enzymes of the choline 
metabolism, like choline kinase, are up-regulated in 
prostate  cancer  cells  [15-16].  Additionally,  an  in-
creased expression of choline transporters and an el-
evated  choline  transportation  rate  have  been  de-
scribed [16-19]. 
The use of [11C]- and [18F]-labelled choline deri-
vates for the detection of primary prostate cancer has 
been examined in many studies with conflicting re-
sults,  for  an  overview  see  Souvatzoglou  et  al.  [20]. 
While  some  studies  with  selected  patient  groups 
demonstrated  high  sensitivities  for  the  detection  of 
primary  prostate  cancer  [21-23],  other  studies  re-
ported lower detection rates [24-28]. Importantly the 
detection rate of primary prostate cancer using [11C]- 
and [18F]choline-PET/CT is influenced by the tumor 
configuration with small and partly `rind-like` carci-
nomas (onion ring form of growth) often not detected 
[28]. Furthermore, choline PET/CT has shown limited 
specificity. 
This article reviews the use of PET and PET/CT 
using  molecular  imaging  probes  in  prostate  cancer 
with special emphasis on the use of radiolabeled cho-
line  derivates  for  diagnosis  and  staging  of  patients 
with primary prostate cancer. 
Diagnosis of primary prostate cancer 
CT 
Morphological  imaging  techniques  such  as 
TRUS, CT and MRI have demonstrated only limited 
accuracy  for  diagnosis  of  primary  prostate  cancer. 
Regarding the diagnosis of primary prostate cancer, 
CT cannot differentiate benign from malignant pros-
tatic tissue; therefore the specificity in differentiating 
malignant  from  benign  prostatic  lesions  is  limited 
[14]. For lymph node staging CT has also shown lim-
ited sensitivity (36% in a meta-analysis) [29]. 
At present, CT imaging has no decisive role in 
the diagnosis of primary prostate cancer [30]. The use 
of CT imaging is recommended for patients at high 
risk with a PSA level > 20 ng/ml, Gleason score > 7 
and/or clinical tumor stage T3 or higher [31] or for 
detection of lymph node metastases and lymph node 
staging [30].  
MRI  
For detection, localization and definition of local 
extent  of  prostate  cancer  morphological  and  func-
tional MRI techniques are increasingly being used. In 
T2-weighted  MRI,  prostate  cancer  tissue  normally 
presents with a decreased signal intensity compared 
to the high signal intensity of the normal peripheral 
zone [30]. The detection rate of primary prostate can-
cer using MRI is superior compared to DRE and TRUS 
[32].  This  result  was  corroborated  by  Hricak  et  al. 
(2007)  who  reported  that  MRI  imaging  performed 
better than CT, DRE and TRUS in the evaluation of Theranostics 2012, 2(3) 
 
http://www.thno.org 
320 
uni- or bilateral disease of stage T2 and T4 [33] with 
sensitivity of 80% and specificity of 99% for detection 
of seminal vesicle invasion. Determination of the local 
tumor stage can be improved by using high resolution 
endorectal coil MRI [34]. Bloch et al. (2007) reported 
sensitivity between 75% and 89% for the determina-
tion  of  extracapsular  extension  with 
high-spatial-resolution  dynamic  contrast-enhanced 
and T2-weighted MRI [35]. High resolution endorec-
tal coil MRI is recommended for use as an additional 
imaging  modality  in  patients  with  negative  biopsy 
and suspected primary prostate cancer and patients 
with a medium or high probability of extraprostatic 
disease [36].  
Recent  studies  have  evaluated  functional  and 
molecular  MRI  techniques  for  primary  and  nodal 
staging of prostate cancer such as diffusion weighted 
imaging (DWI) and dynamic-contrast-enhanced MRI 
as well as magnetic resonance spectroscopy (MRS). In 
some  studies  multiparametric  MRI  modalities  were 
compared with choline PET/CT imaging. 
Wefer et al. compared the accuracy of endorectal 
MRI and MRS with that of sextant biopsy for the sex-
tant localization of prostate cancer. For sextant local-
ization of prostate cancer, MRI and MRS were more 
sensitive but less specific than biopsy (67% and 76% 
versus  50%,  and  69%  and  68%  versus  82%,  respec-
tively). The sensitivity of sextant biopsy was signifi-
cantly  lower  in  the  prostate  apex  than  in  the  mid 
prostate or prostate base (38% versus 52% and 62%, 
respectively).  These  results  showed  that  MRI  and 
MRS had an accuracy similar to biopsy for intrapros-
tatic localization of cancer and that they were more 
accurate  than  biopsy  in  the  prostate  apex  [37]. 
Mazaheri et al. reported that combined MRS and DWI 
MRI improved differentiation between prostate can-
cer and prostatitis, especially in the peripheral zone 
[38]. Testa et al. compared the diagnostic performance 
of MRI, 3-dimensional MRS, combined MRI and MRS 
and [11C]choline for imaging primary prostate cancer. 
The authors showed that the sensitivity of [11C]choline 
PET/CT was lower in comparison to MRS and MRI 
combined  with  MRS  (sensitivity  of  55%  for 
[11C]choline PET/CT, 54% for MRI and 81% for MRS, 
respectively) [39]. On contrary, Yamaguchi et al. re-
ported a higher sensitivity of [11C]choline PET com-
pared to MRI only and MRI/MRS in the detection of 
primary prostate cancer (100% for PET, 60% for MRI 
and 65% for MRI/MRS) [23]. Eschmann et al. (2007) 
compared [11C]choline PET/CT with whole-body MRI 
for staging prostate cancer. The authors reported sen-
sitivity and specificity of 97% and 77%, respectively, 
for choline PET/CT and 79% and 94%, respectively, 
for whole-body MRI [40]. 
The use of MRI with ultrasmall superparamag-
netic iron oxide (USPIO) was reported to be signifi-
cantly better than conventional MRI in differentiating 
benign from malignant lymph nodes and showed a 
high sensitivity in detection of prostate cancer lymph 
nodes [41].  
Eiber et al. showed the feasibility of using DWI 
for  detection  of  lymph  node  metastases  in  patients 
with primary prostate and recurrent prostate cancer 
with a diagnostic accuracy of 85.6% [42]. 
Beer et al. examined 14 prostate cancer patients 
with  [11C]choline  PET/CT  and  DWI  comparing  the 
functional  parameters  SUV  in  PET  and  Apparent 
Diffusion Coefficient (ADC) in DWI of lymph nodes 
in prostate cancer using a linear regression analysis. 
ADC values and SUV showed a moderate but highly 
significant inverse correlation (r = -0.5144, p < 0.0001). 
In lymph nodes with low ADC values, the dispersion 
of  SUV  was  more  pronounced.  Moreover,  a  highly 
significant  difference  was  observed  for  mean  ADC 
values and SUV in lymph nodes considered as benign 
or  malignant  by  follow-up/histopathology  (ADC 
1.60 ± 0.24  vs.  1.09 ± 0.23 × 10(-3)  mm(2)/s;  SUV 
1.82 ± 0.57  vs.  4.68 ± 03.12;  p < 0.0001,  respectively) 
[43]. 
Based on the available literature, MRI imaging of 
prostate cancer is not routinely used in the diagnosis 
of primary prostate cancer at the present time. MRI 
can  be  useful  for  the  evaluation  of  seminal  vesicle 
infiltration  and/or  the  diagnosis  of  extra-capsular 
spread  with  potential  implications  on  staging  and 
subsequent  treatment.  Furthermore,  MRI  may  be 
useful as additional diagnostic tool in patients with 
multiple negative biopsies. In patients with high risk 
prostate cancer, an MRI (or CT) can be useful if the 
decision on the therapeutic strategy is under way.  
FDG 
The  use  of  [18F]fluorodeoxyglucose  (FDG)  in 
oncology is based on an increased glucose uptake in 
cancer  cells  by  increased  glucose  transport  through 
the cell membrane of malignant cells and an overex-
pression of the enzyme hexokinase. In the diagnosis of 
primary and metastatic prostate cancer, FDG PET/CT 
imaging has shown limited efficacy due to FDG up-
take both in prostate cancer cells and benign prostatic 
tissue  such  as  benign  prostatic  hyperplasia  [44-45]. 
Liu et al. (2001) and Hofer et al. (1999) showed a lim-
ited value for FDG-PET concerning differentiation of 
prostate  hyperplasia,  prostate  carcinoma  and  local 
recurrence  [3,  46].  Relatively  low  FDG  uptake  has 
been  attributed  to  a  relatively  slow  metabolic  rate 
with a lower expression of glucose transport proteins 
of prostate cancer cells in comparison to other cancers. Theranostics 2012, 2(3) 
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There  is  a  relationship  between  differentiation  of 
prostate cancer cells and FDG uptake: low differenti-
ated prostate cancer cells show higher FDG uptake in 
comparison  to  higher  differentiated  prostate  cancer 
cells (Fig. 1). FDG shows renal excretion which leads 
to activity accumulation in the ureters and the bladder 
potentially obscuring the target organ and the adja-
cent tissues like seminal vesicles, hampering the de-
tection  of  prostate  cancer  [47].  Oyama  et  al.  (1999) 
reported a sensitivity of 64% in detection of primary 
prostate cancer with a tendency for higher FDG up-
take in tumors with higher Gleason score [48]. This 
result was confirmed by Melchior et al. (1999) who 
reported higher FDG accumulation in poorly differ-
entiated  prostate  cancer  than  in  low  grade  prostate 
cancer [49]. Additionally, Jadvar et al. demonstrated 
that  FDG  uptake  was  higher  in  andro-
gen-independent  than  androgen-sensitive  human 
prostate  cancer  xenografts  and  androgen  ablation 
caused a significant decrease in tumor FDG uptake of 
about 55% [50], suggesting that higher FDG accumu-
lation  may  not  only  be  observed  in  andro-
gen-independent  tumors  in  comparison  to  andro-
gen-sensitive tumors but also that androgen may also 
have a modulatory effect on the glucose metabolism 
of  androgen-sensitive  prostate  cancer  [45].  Schöder 
and Larson have summarized possible explanations 
for the poor performance of FDG PET/CT in primary 
diagnosis  of  prostate  cancer:  a  relatively  low  meta-
bolic rate, location of the prostate adjacent to the uri-
nary bladder and lack of appropriate patient selection 
[51]. 
 
 
 
 
Fig. 1. 72 year old patient with biopsy proven prostate cancer, PSA 7,38 ng/ml, referred for [18F]FDG PET/CT for primary staging. 
[18F]FDG PET/CT revealed advanced disease of primary prostate cancer, iliacal lymph node metastases and bone metastasis (A 1-3) CT 
scan, (B 1-3) PET scan, (C 1-3) PET/CT fused images. 
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ACETATE 
[11C]acetate uptake in tumor cells is related to an 
enhanced lipid synthesis, reflecting the increased lipid 
synthesis during tumor growth of cancer cells [52]. An 
increase in fatty acid synthesis and an overexpression 
of  the  key  enzyme  fatty  acid  synthase  have  been 
demonstrated in prostate cancer cells [53]. In a com-
parative study by Oyama et al. [11C]acetate proved to 
be superior to [18F]FDG for imaging prostate cancer 
[54].  However,  [11C]acetate  is  not  a  cancer-specific 
tracer  and  also  accumulates  in  normal  and  hyper-
plastic tissue. Kato et al. (2002) showed that there was 
a  significant  overlap  of  uptake  in  normal  prostate, 
benign prostate hyperplasia and prostate cancer [55]. 
Wachter et al. (2006) showed that combined PET/CT 
imaging or PET/MRI imaging may be helpful in de-
fining the exact anatomical localization and classifica-
tion  of  acetate  PET  findings  [56].  A  recent  study 
showed a limited accuracy of 71% in the detection of 
prostate cancer and a lack of information on cancer 
aggressiveness using [11C]acetate PET/CT [57].  
At the moment the use of [11C]acetate PET/CT is 
not recommended in the diagnosis of primary pros-
tate cancer. 
 
METHIONINE 
Uptake  of  [11C]methionine  is  related  to  an  in-
creased amino acid transport and protein synthesis of 
cancer cells. There are only few studies evaluating the 
use of [11C]methionine PET/CT in imaging prostate 
cancer.  Nunez  et  al.  compared  FDG-PET  and 
[11C]methionine PET and reported a higher detection 
for [11C]methionine in comparison to FDG [5]. Shiiba 
et  al.  evaluated  the  potential  of  [11C]methionine 
PET/CT and [18F]FDG PET/CT to diagnose primary 
prostate  cancer.  SUVmax  was  compared  with  the 
pathological findings. The authors divided the tumors 
into three groups. If the summed Gleason score of the 
specimens was 5 or less, they were grouped as NG (no 
grade with the Gleason score). If the summed Gleason 
score was 6 or 7, the tumors were defined as LG (low 
Gleason  score  group),  and  if  the  summed  Gleason 
score was 8, 9 or 10, the tumors were classified as HG 
(high Gleason score group). There was no significant 
difference  between  [11C]methionine  and  [18F]FDG 
PET/CT  in  diagnosing  prostate  cancer  of  high 
Gleason  score  (≥8).  Therefore,  [11C]methionine  ap-
peared to be useful for detecting  prostate cancer of 
both low and high Gleason score [58]. 
However,  further  studies  are  needed  to  assess 
the value of [11C]methionine PET/CT in diagnosing 
primary prostate cancer. 
FDHT 
[18F]fluorodihydrotestosterone (FDHT) is anoth-
er innovative PET tracer that has been introduced for 
imaging  prostate  cancer.  PET/CT  imaging  using 
FDHT  is  based  on  an  increased  androgen  receptor 
expression. However, expression of androgen recep-
tors  is  similar  in  prostate  cancer  cells  compared  to 
normal prostate cells. Therefore, [18F]FDHT might be 
more suitable for therapy monitoring than for diag-
nosing  primary  prostate  cancer.  Larson  et  al  and 
Dehdashti et al. showed that testosterone might lead 
to a decrease of [18F]FDHT uptake in prostate cancer 
cells [7, 9].  
CHOLINE 
The value of PET and PET/CT using [11C]- and 
[18F]-  labeled  choline  derivates  for  the  diagnosis  of 
primary prostate cancer has been examined in several 
studies  with  partially  controversial  results  [8,  11, 
21-27, 59-69] (Table 1). For detection of local prostate 
cancer mean values for sensitivity and specificity vary 
between 73% and 91% (Fig. 2 and 3). The majority of 
reported sensitivities were based on a patient-based 
analysis, which showed better results (98-100%) than 
the lesion-based analysis. Some of the studies with a 
given selection of patient groups showed higher sen-
sitivities for the detection of primary prostate cancer 
[21-23], while other studies reported lower detection 
rates [24-28].  
The following studies reported a high sensitivity 
for the detection of primary prostate cancer using PET 
and  PET/CT  with  radioactively  labelled  choline 
derivates. De Jong et al. prospectively evaluated the 
visualization  of  primary  prostate  carcinomas  with 
[11C]Choline  PET  in  patients  with  biopsy-proven 
prostate cancer in comparison with benign changes of 
the  prostate.  Normal  prostate  and  prostate  cancer 
tissue  showed  mean  SUV  of  2.3  (1.3-3.2)  and  5 
(2.4-9.5), respectively. In 24 of 25 patients there was a 
focal increased choline uptake [60]. Sutinen et al. ex-
amined 14 patients with histologically proven pros-
tate cancer using [11C]Choline PET. In all 14 patients 
visualization and detection of primary prostate cancer 
was possible by means of an increased choline uptake 
[68].  Kwee  et  al.  examined  17  patients  using 
[18F]fluorocholine PET. Eleven of the 17 patients had 
bilateral positive findings in histopathology, 6 of 17 
had unilateral positive findings. In all of these 6 pa-
tients  showing  unilateral  disease  the  affected  side 
could correctly be identified using a SUVmax cut-off of 
>3.3 [21]. Yamaguchi et al. compared [11C]choline PET 
with MRI and MRS regarding localization and evalu-
ation  of  lesions  in  patients  with  prostate  cancer. 
[11C]choline  PET  identified  20  out  of  20  primary Theranostics 2012, 2(3) 
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prostate carcinomas (sensitivity 100%) while the sen-
sitivity for MRI and MRS were only 60% (12/20) and 
65% (13/20), respectively. A weak linear correlation 
was found between SUVmax and PSA values (p < 0.05) 
as  well  as  between  SUVmax  and  the  ratio  of 
Cho+Cr/Ci (r=0.49, p < 0.05). Relating to localization 
of the lesions [11C]choline PET was concordant in 13 
patients  (out  of  16  patients  that  underwent  total 
prostatectomy)  with  histopathological  results  while 
this was true for MRS in only 50% (8/16) of the cases 
[23]. Yoshida et al. evaluated the use of [11C]choline 
PET  in  staging  primary  prostate  cancer.  Primary 
prostate cancer could be identified by  means  of in-
creased choline uptake in 5 of 6 patients (mean SUV of 
4.21) (range 2.99 to 6.2), and only in one patient with 
primary prostate cancer could not be identified cor-
rectly using [11C]choline PET [69]. Reske et al. found a 
SUVmax cut-off of 2.65 with an associated area under 
the curve of 0.89±0.01 in the ROC analysis for correct 
prediction of prostate cancer. Regions with prostate 
cancer could be identified in all patients (26/26) using 
[11C]choline  PET/CT,  resulting  in  a  sensitivity  of 
100%. Furthermore the authors did not find a correla-
tion  between  [11C]choline  SUV  and  PSA  value  and 
Gleason-Score  but  found  a  correlation  with  T  stage 
[22]. These results showing high sensitivities of cho-
line  PET/CT  for  the  detection  of  primary  prostate 
cancer could not be confirmed by a significant num-
ber  of  studies  that  reported  limited  sensitivities  for 
primary staging of prostate cancer. 
 
 
 
Fig. 2. 71 year old patient with biopsy proven prostate cancer, initial PSA 193 ng/ml, referred for [18F]choline PET/CT for primary staging. 
[18F]choline PET/CT revealed adcanced disease (primary prostate cancer, iliacal and pararectal lymph node metastases) (A 1-3) CT scan, 
(B 1-3) PET scan, (C 1-3) PET/CT fused images. Theranostics 2012, 2(3) 
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Fig. 3. 75 year old patient under of primary prostate cancer and increasing PSA> 40 ng/ml, referred for [18F]choline PET/CT for primary 
staging due to multiple negative biopies. [18F]choline PET/CT revealed advanced disease with multilocular prostate cancer, lymph node 
metastasis and bone metastasis (A 1-3) CT scan, (B 1-3) PET scan, (C 1-3) PET/CT fused images. 
 
Table 1. Diagnostic efficacy of [
18F]Choline and [
11C]Choline PET and PET/CT in patients with primary prostate cancer 
(modified and updated from [12]). *Sextant-based comparison with histology. **Uptake ratio of lesion to muscle was 
compared with histology. 
Tracer  Ref.  Author  Year  Modus  Pts. (n)  Local tumour     Lymph nodes    
                  Sensitivity (%)  Specificity (%)  Sensitivity (%)  Specificity (%) 
[18F]FCH  [21]   Kwee  2005  PET  17  100  -  -  - 
   [66]  Schmid  2005  PET/CT  19  100  -  -  - 
   [63]  Kwee  2006  PET  26  100  -  -  - 
   [62]  Husarik  2008  PET/CT  43  98  -  33  100 
   [67]  Steuber  2010  PET/CT  20  -  -  0  100 
   [59]  Beheshti  2010  PET/CT  130  n.c.  n.c.  45  96 
   [70]   Poulsen  2010  PET/CT  25  -  -  100  95 
[11C]Cho   [8]  Kotzerke  2000  PET  23  100  -  50  90 
   [60]  de Jong  2002  PET  25  100  -  80  95 
   [71]  de Jong  2003  PET  67  -  -  80  96 Theranostics 2012, 2(3) 
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Tracer  Ref.  Author  Year  Modus  Pts. (n)  Local tumour     Lymph nodes    
                  Sensitivity (%)  Specificity (%)  Sensitivity (%)  Specificity (%) 
   [68]  Sutinen  2004  PET  14  100  -  -  - 
   [23]  Yamaguchi  2005  PET  20  100  -  -  - 
   [69]  Yoshida  2005  PET  13  -  -  -  - 
   [24]  Farsad*  2005  PET/CT  36  66  81  -  - 
   [22]  Reske*  2006  PET/CT  26  100  -  -  - 
   [27]  Scher  2007  PET/CT  58  86  70  -  - 
   [26]  Martorana*  2006  PET/CT  43  66  84  -  - 
   [25]  Giovacchini*  2008  PET/CT  19  72  43  -  - 
   [65]  Schiavina  2008  PET/CT  57  -  -  60  98 
   [64]  Li**  2008  PET/CT  49  90  86  -  - 
   [11]  Watanabe  2010  PET  43  73  59  -  - 
   [28]  Souvatzoglou*  2011  PET/CT  43  79   -    -    -  
Sum              816             
Mean                 89,4  70,5  56  96.2 
Median                 99  75,5  55  96 
 
 
 
Farsad  et  al.  examined  the  usefulness  of 
[11C]choline PET/CT for imaging of primary prostate 
cancer  correlating  imaging  studies  and  histopatho-
logic  examinations  of  axial  step  sections.  Thirty  six 
patients  that  were  included  in  the  study  had  biop-
sy-proven  prostate  cancer  and  underwent  radical 
prostatectomy and pelvic lymph node dissection after 
[11C]choline PET/CT. On a sextant basis histopathol-
ogy  was  used  to  evaluate  [11C]choline  uptake  with 
respect to prostate cancer, prostatitis, benign prostatic 
hyperplasia and high-grade intraepithelial neoplasia 
(HGPIN). PET detected 108 biopsies with suspicious 
[11C]choline uptake (of which 94 were located in the 
area of a tumor) and 108 biopsy cores with normal 
[11C]choline uptake (of which 49 were false negative), 
resulting in a sensitivity of 66% [24]. Scher et al. con-
ducted  a  study  exploring  the  diagnostic  value  of 
[11C]choline PET and PET/CT in a group of 58 pa-
tients with suspected prostate cancer. Prostate cancer 
prevalence  in  this  group  was  63.8%  (37/58).  Mean 
SUVmax for prostate cancer was 4.3±1.7 (2.2-9.8). Mean 
SUVmax for patients without prostate carcinoma was 
3.3±0.9  (1.4-4.7)  (p=0.027).  Prostate  cancers  of  the  5 
patients  with  negative  PET  and  PET/CT  scans 
demonstrated  SUVmax  values  between  2.2  and  3.3. 
[11C]choline PET and PET/CT demonstrated a sensi-
tivity of 86.5% (32/37), a positive predictive value of 
80.0%, a negative predictive value of 72.2% and ac-
curacy of 77.6% [27]. Martorana et al. examined the 
sensitivity of PET and CT for intraprostatic localiza-
tion of prostate cancer on the basis of nodular lesions 
and  a  transrectal  prostate  biopsy  (12  cores)  [26]. 
PET/CT demonstrated a sensitivity of 83%, 66% and 
4%,  respectively,  for  localization  of  nodular  lesions 
measuring more than 5 mm, for all lesions and lesions 
smaller than 5 mm, respectively. Logistic regression 
analysis revealed that only size had an influence on 
sensitivity.  Based  on  sextant  biopsy  PET/CT  had  a 
slightly better sensitivity than transrectal ultrasound 
(66%  vs.  61%,  p=0.434).  For  determination  of  ex-
traprostatic extension, sensitivity of PET/CT was low 
in comparison with MRI (22% vs. 63%, p=0.001) [26]. 
Giovacchini et al. performed [11C]choline PET/CT in 
19 patients comparing post-prostatectomy histopath-
ologic  axial  step  sections  with  [11C]choline  PET/CT 
imaging.  With  a  SUVmax  cut-off  of  2.5,  [11C]choline 
PET/CT  had  a  sensitivity  of  72%  which  concurred 
with the studies of Farsad et al. [24], Scher et al. [27] 
and Martorana et al. [26]. Souvatzoglou et al. exam-
ined 43 patients with primary prostate cancer com-
paring  imaging  and  histopathology  using  a  seg-
ment-based analysis. They showed that the sensitivity 
of [11C]choline PET/CT depends on the tumor con-
figuration.  Prostate  segments  involved  by  cancer 
could  be  identified  in  79%  of  the  patients  using 
[11C]choline  PET/CT.  Tumor  configuration  was  the 
only  factor  significantly  influencing  tumour  predic-
tion (p<0.001) [28]. 
Therefore  there  is  emerging  evidence  as  dis-
cussed by Souvatzoglou et al. that tumor configura-
tion seems to be a major factor influencing the detec-
tion of primary prostate cancer. The detection of small 
and partly `rind-like` carcinomas (onion ring form of 
growth) is often not possible [28]. Theranostics 2012, 2(3) 
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Besides the limited sensitivity, the differentiation 
between benign prostatic hyperplasia (BPH), prosta-
titis or high-grade intraepithelial neoplasia (HGPIN) 
is not always possible in primary staging of prostate 
cancer using choline PET/CT [23-26, 66, 68-69].  
Reske et al. showed that choline uptake was sig-
nificantly higher in prostate cancer in comparison to 
normal  prostate  tissue,  prostatitis  and  other  benign 
lesions  (p<0.001).  (SUVmean  of  benign  prostatic  le-
sion 2.0 +/- 0.6; SUVmean  of prostate cancer 3.5 +/- 
1.3). The authors reported a specificity of 87% using a 
SUVmax threshold of 2.65 [22]. Scher et al. reported a 
specificity of 61.9% (13/21) for the diagnosis of pri-
mary prostate cancer. The authors concluded that a 
differentiation between benign and malignant lesions 
is possible in most cases if imaging analysis is mainly 
based on qualitative criteria. The authors discussed a 
SUVmax cut-off of 3.3 for differentiation of benign and 
malignant lesions (with a sensitivity of 70.3% and a 
specificity of 57.1%) [27]. Kwee et al. reported a sig-
nificant higher SUVmax in biopsy proven positive sex-
tants compared to non-malignant sextans (mean value 
5.5 vs. 3.3, p<0.001). Therefore the authors concluded 
that  differentiation  between  benign  and  malignant 
prostatic lesions was possible using [18F]choline PET. 
Kwee et al. (2006) also evaluated the efficacy of de-
layed  [18F]choline  PET  imaging  or  imaging  at  two 
time  points  for  the  localization  of  primary  prostate 
carcinoma (7 minutes and 1 hour). The mean SUVmax 
for malignant findings significantly increased from 7.6 
to 8.6 between early and delayed acquisition (mean 
retention index +14%, 95% confidence interval 6-22%, 
p = 0.002). The mean SUVmax for presumably benign 
lesions significantly decreased between the initial and 
the late image (4.8 to 3.9). The mean ratio between 
malignant and benign lesions increased significantly 
(1.4 to 1.8 in the late images (p = 0.0003)) [63]. Piert et 
al. examined 14 patients suffering from prostate can-
cer using [11C]choline PET/CT. Tumor-to-background 
ratios Tmean /B- and Tmax/B-were calculated. Lesions 
with a Gleason score of 4+3 or higher showed signif-
icantly higher Tmean /B- and Tmax/B-ratios in compar-
ison to the tumours with a Gleason score of 3+4 and 
lower.  The  authors  also  reported  a  correlation  be-
tween  MIB-1/Ki-67-expression,  Gleason  score  and 
Tmean/B- and Tmax/B-ratios. Choline uptake correlated 
positively  with the proliferation  index  [72]. Giovac-
chini et al. reported a specificity of 43% using a SU-
Vmax cut- off of 2.5 for differentiation between benign 
and  malignant  prostatic  lesions.  The  authors  found 
the co-existence of prostatitis, HGPIN and BPH to be a 
main limitation of their study [25]. Schmid et al., Yo-
shida et al. and Yamaguchi et al. confirmed these re-
sults by showing that there was a significant overlap 
of choline uptake between BPH and prostate cancer 
which resulted in a limited specificity in the detetion 
of primay prostate cancer using choline PET/CT [23, 
66, 69]. Sutinen et al. calculated kinetic parameters on 
the basis of graphical analysis of the dynamic uptake 
in the prostate within 30 minutes. The mean Ki-values 
were 0.205±0.089 min-1 (0.128-0.351; n=7) and 5.6±3.2 
(1.9-15.5;  n=15)  for  untreated  tumours  and  3.5±1.0 
(2.0-4.5; n=4) and 0.119±0.076 min-1 (0.065-0.173; n=2) 
for  benign  prostatic  enlargement.  The  authors  re-
ported a high correlation between the Ki-values and 
SUV (r = 0.964, p = 0.0005) while there was no corre-
lation  for  [11C]Choline  uptake  in  the  tumour  and 
grade of differentiation, Gleason-Score, volume of the 
prostate  and  PSA  value.  The  authors  demonstrated 
that  a  high  [11C]choline  uptake  not  only  exists  in 
prostate  cancer  but  also  in  prostate  hyperplasia 
meaning  there  is  an  extensive  overlap  in  Ki-values 
and SUV [68]. Martorana et al. showed that SUVmax 
was  significantly  higher  in  malignant  lesions  com-
pared to benign lesion (p=0.027). However there was 
no  statistically  significant  difference  between 
false-positive  and  false-negative  findings.  Based  on 
sextant biopsy, PET/CT had a slightly better sensitiv-
ity than transrectal ultrasound (66% vs. 61%, p= 0.434) 
but it was less specific (84% vs. 97%, p=0.008)  [26]. 
Farsad et al. confirmed that benign entities such as 
HGPIN, prostatitis and BPH also show a high choline 
uptake. The authors reported a specificity of 81% for 
the detection of primary prostate cancer that was not 
significantly  different  from  that  with  HGPIN  [24]. 
Beheshti et al. examined 130 patients preoperatively 
using [18F]fluorocholine (FCH) PET/CT. Differentia-
tion between prostate cancer and prostatitis was not 
possible  due  to  intense  FCH  accumulation  of  in-
flammatory  lesions  [59].  Souvatzoglou  et  al.  con-
firmed  the  results  concerning  limited  specificity  of 
choline PET/CT in primary staging of prostate cancer. 
In  their  study  there  was  no  statistically  significant 
difference between SUVmax of prostate cancer, benign 
prostate hyperplasia (p=0.102) or prostatitis (p=0.054) 
[28]. 
In summary, choline PET/CT cannot be recom-
mended  as  a  first-line  screening  procedure  for  the 
diagnosis of primary prostate cancer in men at risk. It 
might  play  a  role  in  the  detection  of  clinically  sus-
pected  prostate  cancer  with  repeatedly  negative 
prostate biopsies. 
With respect to lymph node staging only a few 
studies reported results for sensitivity and specificity 
of  choline  PET/CT  (see  table  1).  For  lymph  node 
staging in prostate cancer, de Jong et al. showed, that 
[11C]choline  PET  identified  metastatic  pelvic  lymph 
nodes with a size between 0.5 and 3 cm with a mean Theranostics 2012, 2(3) 
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SUV of 4.7 (2.9-9.1). The authors reported 19 correct 
negative findings in 19 patients without lymph node 
metastases  and  one  false  positive  [11C]choline  en-
hancement  in  a  lymph  node  with  inflammatory 
changes [60]. In a further study de Jong et al. explored 
the accuracy of [11C]choline PET/CT in the preopera-
tive  non-invasive  staging  of  pelvic  lymph  nodes  in 
patients with prostate cancer, reporting values of 80%, 
96% and 93% for sensitivity, specificity and accuracy, 
respectively [71]. Kotzerke et al. reported sensitivity 
and  specificity  of  50%  and  90%,  respectively,  for 
[11C]choline PET [8]. Schiavina et al. examined 57 pa-
tients  with  biopsy-proven  prostate  cancer  who  had 
intermediate or high risk for lymph node metastases 
using  [11C]choline  PET/CT  prior  to  prostatectomy 
and  extended  pelvic  lymph  node  dissection  [65]. 
[11C]choline PET/CT showed a sensitivity of 60% and 
a specificity of 98% for the detection of lymph node 
metastases. Comparing [11C]choline PET/CT findings 
to  nomograms,  no  statistically  significant  difference 
was  found.  Poulsen  et  al.  examined  25  consecutive 
patients  with  primary  prostate  cancer  with  FCH 
PET/CT.  The  sensitivity  and  specificity  of  FCH 
PET/CT  for  patient  based  lymph  node  staging  of 
prostate cancer was 100% and 95% [70]. The variation 
of  reported  percentage  of  patients  presenting  with 
lymph node metastases with respect to nodal staging 
can possibly be explained with the differences of the 
patient cohorts included in the various studies (low 
risk  vs.  intermediate  vs.  high  risk  patients).  Never-
theless, sensitivity of choline PET/CT seems to be low 
for the detection of small lymph node metastases and 
micrometastases. 
Concerning M-staging, Beheshti et al. and Lang-
steger  et  al.  examined  the  use  of  [11C]-  and 
[18F]-labelled choline PET/CT as well as [18F]fluoride 
PET/CT (which reflects blood flow and osteoblastic 
activity) for imaging of bone metastases of primary 
prostate cancer as well as locally recurrent prostate 
cancer. Beheshti et al. examined thirty-eight patients 
with biopsy-proven prostate cancer (17 of the patients 
preoperatively  and  21  patients  referred  for 
post-operative evaluation of suspected recurrence or 
progression based on clinical algorithms) comparing 
FCH and [18F]fluoride (FNa) PET/CT scanning for the 
detection  of  bone  metastases  from  primary  and  re-
current prostate cancer. In the whole group of 38 pa-
tients  (preoperatively  as  well  as  post-operatively) 
overall  sensitivity,  specificity  and  accuracy  of 
PET/CT in the detection of bone metastases in pros-
tate cancer  were  74% ,  99%  and  85%  for  FCH  and 
81%,  93%  and  86%  for  FNa,  respectively.  FCH 
PET/CT led to a change in the management in 2 of 38 
patients due to the early detection of bone marrow 
metastases [73]. 
In  another  study  Beheshti  et  al.  compared  the 
uptake of FCH in bone metastases in 70 patients (32 
preoperatively with biopsy-proven prostate cancer, 38 
postoperatively with suspected recurrence of prostate 
cancer) in comparison to morphologic changes on CT. 
For all 70 patients (preoperatively as well as postop-
eratively) sensitivity, specificity and accuracy of FCH 
PET/CT in detecting bone metastases from prostate 
cancer were 79%, 97%, and 84%, respectively [74]. 
In  a  prospective  study  Langsteger  et  al.  com-
pared the diagnostic performance of FCH and FNa for 
the detection of bone metastases in 42 patients with 
prostate cancer and a follow up of at least 6 months. 
Overall, bone involvement was present in 22 patients 
and absent in 18. For the whole group of patients (ini-
tial staging as well as patients referred for suspicion of 
recurrence), the patient-based diagnostic performance 
for FCH vs. FNa was 91% vs. 91% for sensitivity, 89% 
vs. 83% for specificity and 90% vs. 88% for accuracy 
(without statistically significant difference). There was 
also no significant difference in site-based diagnostic 
performance in the group of patients referred at initial 
staging. However, in the group of patients referred for 
suspicion of recurrence, FCH was significantly more 
specific  than  FNa  (96%  vs.  91%,  P=0.033  with 
Obuchowski's  correction)  while  sensitivity  was  the 
similar, 89% [75]. 
Concerning M-staging of primary and recurrent 
prostate cancer FCH PET-CT may be superior for the 
early  detection  (i.e.  bone  marrow  involvement  and 
early cortical involvement) of metastatic bone disease. 
In  patients  with  FCH-negative  suspicious  sclerotic 
lesions, a second bone-seeking agent (e.g. FNa) might 
give additional information. 
Conclusion and Outlook 
Choline PET/CT is a clinically valuable tool for 
re-staging patients with increasing PSA serum levels 
after definitive local therapy. However, at the present 
time choline PET/CT cannot be recommended as a 
first-line  screening  procedure  for  primary  prostate 
cancer in men at risk due to its limited sensitivity, its 
dependency  on  tumor configuration and its limited 
specificity  in  differentiating  prostate  cancer  tissue 
form benign pathologies. Choline PET/CT may be of 
value for the detection of clinically suspected prostate 
cancer with multiple negative prostate biopsies. Cho-
line PET/CT plays a role in patient stratification with 
respect to lymph node involvement for primary sur-
gery  and  radiation  therapy.  Therefore  the  potential 
role  of  choline  PET/CT  in  lymph  node  staging  of 
primary prostate cancer will have to be evaluated in 
further studies. Theranostics 2012, 2(3) 
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 Although considerable progress has been made 
in  the  recent  years  with  PET/CT  using  [11C]-  and 
[18F]-labelled  choline  derivates,  diagnostic  perfor-
mance still needs to be improved. Many strategies for 
prostate cancer imaging with novel radiotracers such 
as  bombesin-based  tracers  or  tracers  for  androgen 
receptor  imaging  are  being  assessed  in  preclinical 
studies and in some cases in first clinical feasibility 
studies.  In  the  future  more  tumour-specific  tracers 
may increase the sensitivity and specificity for mul-
timodal  imaging  detection  of  prostate  cancer.  Ad-
vances in hybrid imaging, especially PET/MR, could 
also provide improvement in diagnostic accuracy by 
combining molecular imaging properties of PET with 
high  resolution  and  excellent  soft-tissue  contrast  of 
MRI. 
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